Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
Triple Negative Breast Cancer
About this trial
This is an interventional treatment trial for Triple Negative Breast Cancer focused on measuring Triple negative breast cancer, Platinum, Neoadjuvant
Eligibility Criteria
Inclusion Criteria: Triple-negative breast cancer Stage II and III Exclusion Criteria: Double primaries Male breast cancer Pregnant or lactating women Patients with Eastern Cooperative Oncology Group (ECOG) performance status more than two Patients below 18 years old Initial surgery of the primary site (excluding diagnostic biopsy) Serious concomitant medical illness including clinically significant cardiovascular disease Major surgery or trauma in the previous four weeks
Sites / Locations
- Bangabandhu Sheikh Mujib Medical University
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Platinum-based regimen
Non-platinum based regimen
Patients will be treated with doxorubicin 60 mg/m2 IV on day 1 and cyclophosphamide 600 mg/m2 IV on day 1 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 IV weekly for 12 weeks concurrently with carboplatin (area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles).
Patients will be treated with doxorubicin 60 mg/m2 IV on day 1 and cyclophosphamide 600 mg/m2 IV on day 1 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 IV weekly for 12 weeks.